Tomocube Q1 2026 Sales KRW 2.7B (+320% YoY) but Operating Loss of KRW 1.9B, Securities Filing Violation Risk Remains

Revenue: KRW 2,746M (vs KRW 653M in prior year period, +320% YoY), HT product line 92.5%
Operating loss: KRW 1,865M (vs loss of KRW 2,632M loss, narrowing)
Net loss: KRW 1,355M (vs loss of KRW 2,786M)
Order backlog: KRW 3.56B (vs KRW 1.42B at prior year end, +150%)
Debt ratio: 7.73% (vs 7.01%), Cash and cash equivalents: KRW 19.1B
R&D expense/Sales: 60.8% (KRW 1,669M)
Ongoing FSS investigation for securities filing violation, potential penalty
Overseas subsidiaries (Tomocube USA, Europe) combined net loss KRW 634M
Stock option exercise 61,500 shares, KRW 925M capital inflow from new shares